	Application No.	Applicant(s)
	09/994,165	CASTELLI ET AL.
Notice of Allowability	Examiner	Art Unit
	Konata M. George	1616
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commu GHTS. This application is s	this application. If not included inication will be mailed in due course. <b>THIS</b>
1. This communication is responsive to RCE filed December 2	<u>29, 2003</u> .	
2. X The allowed claim(s) is/are 14, 15 and 18-21 (renumbered	<u>1-6)</u> .	
3. The drawings filed on are accepted by the Examiner	f	
<ul> <li>4. Acknowledgment is made of a claim for foreign priority unall All b) Some* c) None of the: <ol> <li>Certified copies of the priority documents have</li> <li>Certified copies of the priority documents have</li> <li>Copies of the certified copies of the priority documents have</li> <li>International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* Certified copies not received:</li> </ul> Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	been received.  been received in Application cuments have been received of this communication to file	n No I in this national stage application from the
5. A SUBSTITUTE OATH OR DECLARATION must be submi INFORMAL PATENT APPLICATION (PTO-152) which give		
6.  CORRECTED DRAWINGS ( as "replacement sheets") mus	t be submitted.	
(a) Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		· · · · · · · · · · · · · · · · · · ·
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	• • •	_ ,
<ol> <li>DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F</li> </ol>		
Attachment(s)  1.  Notice of References Cited (PTO-892)	5. Notice of Inf	ormal Patent Application (PTO-152)
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)		ımmary (PTO-413), Mail Date .
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date		Amendment/Comment
4.   Examiner's Comment Regarding Requirement for Deposit		Statement of Reasons for Allowance
of Biological Material	9.  Other	

Application/Control Number: 09/994,165

Art Unit: 1616

#### **DETAILED ACTION**

Claims 14, 15 and 18-21 are pending in this application.

### Information Disclosure Statement

1. The information disclosure statement (IDS) submitted on December 29, 2003 and October 27, 2004 was noted and the submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the examiner has considered the information disclosure statement.

# Request for Continued Examination (RCE)

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on December 29, 2003 has been entered.

3. The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious the composition having hypoallergenic or immunomodulatory activity for the treatment of sensitive skin made according to the claimed process. The closet prior art of Murad (US 5,804,168) discloses compositions comprising at least one anti-oxidant component and at least one anti-inflammatory component. The prior art does not teach by combining the two active agents one of the activities, one of the activities is potentiated by the combination of these two components. The closet prior art does not teach a composition comprising a Ginkgo biloba extract and  $\beta$ -glucan together with components that exhibit at least on activity selected from anti-inflammatory, anti-radical and/or anti-allergic or at least two components having two different activities.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### Conclusion

4. Claims 14, 15 and 18-21 are allowed.

Application/Control Number: 09/994,165 Page 4

Art Unit: 1616

## **Telephone Inquiries**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is (571) 272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Konata M. George

SHELLEY A. DODSON PRIMARY EXAMINER